These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34161889)

  • 1. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
    McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Lee Y; Ho RC; Subramaniapillai M; Gill H; Cha DS; Lin K; Teopiz KM; Nasri F; Mansur RB; Kratiuk K; Rosenblat JD
    J Affect Disord; 2021 Sep; 292():714-719. PubMed ID: 34161889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
    J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence.
    Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Subramaniapillai M; Kratiuk K; Majeed A; Nasri F; Gill H; Mansur RB; Rosenblat JD
    Psychiatry Res; 2021 Jun; 300():113860. PubMed ID: 33836470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
    J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
    McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Gill H; Nasri F; Ling R; Teopiz KM; Ho RC; Subramaniapillai M; Kratiuk K; Mansur RB; Jones BDM; Lee Y; Rosenblat JD
    J Affect Disord; 2021 Nov; 294():592-596. PubMed ID: 34332360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment.
    McIntyre RS; Rodrigues NB; Lipsitz O; Lee Y; Cha DS; Gill H; Lui LMW; Subramaniapillai M; Kratiuk K; Ho R; Mansur RB; Rosenblat JD
    J Affect Disord; 2021 Jun; 288():210-216. PubMed ID: 33965843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
    McIntyre RS; Lipsitz O; Rodrigues NB; Lee Y; Cha DS; Vinberg M; Lin K; Malhi GS; Subramaniapillai M; Kratiuk K; Fagiolini A; Gill H; Nasri F; Mansur RB; Suppes T; Ho R; Rosenblat JD
    Bipolar Disord; 2020 Dec; 22(8):831-840. PubMed ID: 32406161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
    Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
    Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Cha DS; Gill H; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
    J Psychiatr Res; 2021 Apr; 136():444-451. PubMed ID: 32948309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Gill H; Subramaniapillai M; Kratiuk K; Nasri F; Mansur RB; Rosenblat JD
    CNS Spectr; 2022 Jun; 27(3):322-330. PubMed ID: 33267928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
    Lipsitz O; Di Vincenzo JD; Rodrigues NB; Cha DS; Lee Y; Greenberg D; Teopiz KM; Ho RC; Cao B; Lin K; Subramaniapillai M; Flint AJ; Kratiuk K; McIntyre RS; Rosenblat JD
    Am J Geriatr Psychiatry; 2021 Sep; 29(9):899-913. PubMed ID: 33478865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).
    McIntyre RS; Rosenblat JD; Rodrigues NB; Lipsitz O; Chen-Li D; Lee JG; Nasri F; Subramaniapillai M; Kratiuk K; Wang A; Gill H; Mansur RB; Ho R; Lin K; Lee Y
    Psychiatry Res; 2021 Aug; 302():113993. PubMed ID: 34034067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence.
    Di Vincenzo JD; Lipsitz O; Rodrigues NB; Jones BDM; Gill H; Lee Y; Lui LMW; Teopiz KM; Ho R; Lin K; Nasri F; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2022 Jan; 307():114321. PubMed ID: 34890909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
    Feifel D; Malcolm B; Boggie D; Lee K
    J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
    Rodrigues NB; McIntyre RS; Lipsitz O; Cha DS; Lee Y; Gill H; Majeed A; Phan L; Nasri F; Ho R; Lin K; Subramaniapillai M; Kratiuk K; Mansur RB; Rosenblat JD
    J Affect Disord; 2020 Nov; 276():570-575. PubMed ID: 32871688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence.
    Di Vincenzo JD; Lipsitz O; Rodrigues NB; Lee Y; Gill H; Kratiuk K; Subramaniapillai M; Mansur R; McIntyre RS; Rosenblat JD
    J Psychiatr Res; 2021 Nov; 143():209-214. PubMed ID: 34507101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
    Ng J; Rosenblat JD; Lui LMW; Teopiz KM; Lee Y; Lipsitz O; Mansur RB; Rodrigues NB; Nasri F; Gill H; Cha DS; Subramaniapillai M; Ho RC; Cao B; McIntyre RS
    J Affect Disord; 2021 Oct; 293():285-294. PubMed ID: 34225208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic and Safety Outcomes of Intravenous Ketamine for Treatment-refractory Depression in a Veteran Population: A Case Series.
    Vitek G; Langenfeld R; Walters RW; Elson A; Driscoll D; Ramaswamy S
    Mil Med; 2023 Jul; 188(7-8):e2242-e2248. PubMed ID: 36539918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.